Search Within

Shanu Modi

  1. "Biostatistics Service"
Formats
  1. Journal Article (34)
  2. Meeting Abstract (32)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (67)
  2. Breast Medicine Service (67)
  3. Department of Medicine (67)
  4. Epidemiology and Biostatistics (67)
  5. Solid Tumor Oncology Division (67)
  6. Survivorship Research (61)

More Groups

People
  1. Clifford Hudis (44)
  2. Sujata Patil (44)
  3. Larry Norton (32)
  4. Sarat Chandarlapaty (28)
  5. Chau Dang (25)
  6. Gabriella D'Andrea-Carlino (23)

More People

Years
  1. 2025 (1)
  2. 2024 (5)
  3. 2023 (4)
  4. 2022 (5)
  5. 2021 (3)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Cancer Research (14)
  3. Clinical Breast Cancer (6)
  4. Clinical Cancer Research (4)
  5. npj Breast Cancer (4)
  6. Breast Cancer Research and Treatment (2)

More Publications

Publishers
  1. American Association for Cancer Research (20)
  2. American Society of Clinical Oncology (17)
  3. Elsevier Inc. (9)
  4. Nature Publishing Group (6)
  5. Oxford University Press (4)
  6. Springer (3)

More Publishers

Results (67)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Modi, S.; Fornier, M.; Lake, D.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Journal Article

    Modi, S.; Seidman, A. D.; Dickler, M.; Moasser, M.; D'Andrea, G.; Moynahan, M. E.; Menell, J.; Panageas, K. S.; Tan, L. K.; Norton, L.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Journal Article

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Cancer Investigation (2005)

    Fulltext@MSK | Save
  • A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Journal Article

    Modi, S.; Currie, V. E.; Seidman, A. D.; Bach, A. M.; Panageas, K. S.; Theodoulou, M.; Moasser, M. M.; D'Andrea, G. M.; Lake, D. E.; Choi, J.; more...
    Clinical Breast Cancer (2005)

    Fulltext@MSK | Save
  • Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Journal Article

    Fornier, M. N.; Modi, S.; Panageas, K. S.; Norton, L.; Hudis, C.
    Cancer (2005)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 (P-HER2) as a marker of clinical resistance to single agent taxane chemotherapy for meta-static breast cancer (MBC)
    Meeting Abstract

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Proceedings of the American Association for Cancer Research Annual Meeting (2003)

    Fulltext@MSK | Save
  • Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
    Journal Article

    Modi, S.; Panageas, K. S.; Duck, E. T.; Bach, A.; Weinstock, N.; Dougherty, J.; Cramer, L.; Hudis, C.; Norton, L.; Seidman, A.
    Journal of Clinical Oncology (2002)

    Fulltext@MSK | Save